Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.
Bianchi
Cristina
C
Department of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, University of Pisa, Pisa, Italy.
Miccoli
Roberto
R
Daniele
Giuseppe
G
Penno
Giuseppe
G
Del Prato
Stefano
S
D000284:Administration, Oral; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D006943:Hyperglycemia / Q000150:complications; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008687:Metformin / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000517:prevention & control; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D008687:Metformin